RCS - Venture Life Group - UltraDEX advertising launch <Origin Href="QuoteRef">VLG.L</Origin>

Venture LifeAnnouncement

10/10/2016 07:06

RNS Number : 0358M
Venture Life Group PLC
10 October 2016
Venture Life Group plc
("Venture Life" or the "Company")
UltraDEX advertising launch
Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces the launch of the new UltraDEX advertising campaign in the UK. 
Since the acquisition of the UltraDEX oral care products range in March 2016, the Company has revitalised the brand, creating a fresh identity and a clearer message on all advertising material and packaging. The range is comprised of a daily oral rinse, toothpaste, oral spray and other inter-dental accessories, and achieved revenues of 1.4 million in the first six months of 2016. The Company's Brands business now represents 20% of its total revenue and the Company remains confident in the growth prospects for UltraDEX, in addition to its other brands, having signed three new distribution agreements for UltraDEX since acquiring it in March 2016.
The campaign, launching today, will run for two weeks and aims to increase brand awareness and encourage product trial among new users. UltraDEX will feature on approximately 4,000 tube cards on the London Underground, meaning a banner advertisement in every train carriage on every line, as well as cross track posters in 91 Underground stations. In conjunction with this, the Company will run an extensive radio campaign in London and the South East and free UltraDEX samples will be given out at Waterloo, Victoria and Liverpool Street stations. A new website (www.ultradex.co.uk) has also been launched and whilst the overall level of advertising is significant for Venture Life it is in line with budgeted plans. It will also support in-store activity amongst Venture Life's key retail partners such as Boots, Tesco, Sainsbury's and Amazon, as the Company continues to grow the retail presence of the brand.
Commenting, Chief Executive Officer of Venture Life, Jerry Randall, said:"The acquisition of UltraDEX has had a big impact on our Brands business and we are expecting it to make a significant contribution towards Group profitability. This campaign is being run initially in the London and South East region as we continue to invest behind the UltraDEX brand and support our retail partners."
If any investors would like a sample of the UltraDEX products, please contact Walbrook PR using the contact details below. 
For further information, please contact:
Venture Life Group PLC
+44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
James Hunter, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)
+44 (0) 20 7886 2500
Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking) 

Turner Pope Investments (TPI) Ltd (Joint Broker)
+44 (0) 20 3621 4120
James Pope/Ben Turner

Walbrook PR
venturelife@walbrookpr.com or +44 (0) 20 7933 8780
Paul McManus/Anna Dunphy
+44 (0) 7980 541 893 / +44 (0) 7876 741 001
About Venture Life (www.venture-life.com) 
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. 
The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 
Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAZDLFBQBFEFBE